Search PubMed⌕ Search

Biomedical subjects

A P Zhu

Publications and source records attributed to A P Zhu.

5 recordsLinked to original sources
PubMed2004

Surface modification using photocrosslinkable chitosan for improving hemocompatibility.

Immobilization of the anticoagulative or antithrombogenic biomolecule has been considered as one of the important methods to improve the blood compatibility of artificial biomaterials. In this study, a novel immobilization reaction scheme was utilized to incorporate O-butyrylchitosan (OBCS) onto the activated glass surface with an aim to develop an anticoagulative substrate. Activation of the glass surface was carried out by silanization and then OBCS was grafted to the silanized surface via a radiation grafting technique. The OBCS-grafted glass surfaces were characterized by electron spectroscopy for chemical analysis (ESCA) and atomic force microscopy (AFM). The blood compatibility of the OBCS-grafted glass was evaluated by platelet rich plasma (PRP) contacting experiments and protein adsorption experiments in vitro. These results have demonstrated that the surface with immobilized OBCS shows much less platelet adhesive and fibrinogen adsorption compared to the control surface. Therefore, the novel reaction scheme proposed here is very promising for future development of an anticoagulative glass substrate.

Blood Coagulation↗
PubMed2003

Preparation and characterization of novel silica-butyrylchitosan hybrid biomaterials.

Novel silica-butyrylchitosan hybrid biomaterials were produced by a sol-gel technique, using butyrylchitosan as the organic species incorporated into the silicon alkoxide (TEOS) based network. 3-acryloxypropyl trimethoxysilane (MPTMS) was used effectively to combine the organic and inorganic species to form uniform hybrid biomaterials. All the samples made were in the form of thin, flexible films with transparent clarity. The blood-clotting and platelet adhesion assay confirmed that these hybrid biomaterials displayed potential good blood compatibility.

Journal Article↗
PubMed2001

[Advances of construction of tissue engineered blood vessels].

OBJECTIVE: To discuss the approaches of tissue engineered blood vessels (TEBV) reconstruction. METHODS: The recent literatures about TEBV were widely reviewed. We summarized various types of biomaterials served as scaffold for TEBV and evaluated the construction model of TEBV. And the biological properties of some TEBV were compared. RESULTS: Although the final model of construction of TEBV was not clear, reports in the last two years had shown several important advances in this exciting field. CONCLUSION: Mimicry of some or all of the properties of three layers of natural healthy blood vessels has been the strategy of all TEBV approaches.

Biocompatible Materials↗
PubMed1997

[Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia].

A clinical trial was conducted in order to evaluate the therapeutic effect and side effects of low-dose all-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL). First of all, we compared the pharmacokinetic features in normal individuals with a single oral dose of ATRA at 15 mg/m2 and 45 mg/m2, respectively. The results showed that maximal plasma concentration with oral ATRA at 15 mg/m2 was high enough (10(-6) mol/L) to induce APL cell differentiation. Based on these results, 27 cases of de novo APL patients were treated with oral ATRA at a dose of 15-20 mg/m2/day and 24 of the 26 (92%) evaluable cases achieved clinical complete remission (CR) after 13 to 67 dyas of ATRA treatment. No patient experienced retinoic acid syndrome (RAS) and DIC. The Cmax with a single dose of ATRA on day 1 of treatment and immediately after obtaining of CR with ATRA in three cases demonstrated similar values in one patient and an about 2 fold decrease in two patients. Moreover comparison with a relatively well-matched previous group of 20 APL patients treated with high-dose ATRA showed that low-dose ATRA is as effective as high-dose in treating APL patients and may provide the advantages of decrease of the degree of hyperleukocytosis and side effects.

Adolescent↗